Abstract: A method and assembly for electrochemically identifying target nucleotide sequences. The method includes supplying a biological sample that may contain a predetermined target nucleotide sequence; supplying activatable amplification materials comprising free nucleotides to form replicated target nucleotide sequences; supplying an oxido-reducible compound capable of being inserted during replication between the nucleotides forming the replicated target sequences; and activating the activatable amplification materials before applying an electric field to the sample in order to activate the oxido-reducible compound. The replicated target sequences cause inhibition of electrochemical activity of the inserted oxido-reducible compound, and the presence of the predetermined target nucleotide sequence is determined in instances where the electric current decreases.

Abstract: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stem cells or growth factors.

Abstract: The present invention relates generally to a hydrogel releasing glucose in a time-controlled manner, to medical applications thereof, and to a method for preparing said hydrogel.

Abstract: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors.

Abstract: The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.

Abstract: The present invention concerns a method for obtaining a functional parameter of a muscle having a part, the method comprising the steps of: a) applying ultrasound waves to the muscle, b) collecting the ultrasound waves retrodiffused by the muscle at a plurality of times, to obtain collected ultrasound waves, c) determining a first plurality of values representative of stiffness values of one part at a first plurality of times by using the collected ultrasound waves, d) determining a second plurality of values representative of deformation values of said part at a second plurality of times by using the collected ultrasound waves, and e) deducing at least one functional parameter based on the first plurality of values and the second plurality of values. The invention also concerns a corresponding device.

Abstract: The invention relates to an optical device for measuring the position of an object along a first axis, the object being subjected to light radiations emitted by a light source.

Abstract: The invention relates to the field of cardiovascular resuscitation and, more specifically, it concerns a novel method of monitoring the ventriculo-aortic coupling of at-risk patients on the basis of the aortic pressure/flow loop of the patient and the zoning of this loop.

Abstract: A microwave oven comprising a cavity in which a material can be placed for heating and a magnetron for generating a microwave. The microwave oven further comprises an electromagnetic element adapted to interact with microwaves into the cavity and a control unit that provides a control signal to the electromagnetic element for modifying an impedance of the electromagnetic element during time of heating.

Abstract: The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group consisting of miR-155, miR-10a, miR-92a and miR-31 in a blood sample obtained from the heart recipient, ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) and iii) and concluding that the recipient has a high risk of developing acute rejection when the level the expression level (ELi) determined at step i) is different (higher or lower) than the predetermined reference level (ELRi).

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.

Abstract: The present invention relates to porphyrins of formula (I): wherein R1 to R6, R1? to R6?, X, X? Y and Y? are as described in claim 1. The invention also relates to complexes of said porphyrins with transition metals, in particular iron, preferably as Fe(III) or Fe(0) complex, and salts thereof, use thereof as catalysts for the selective electrochemical reduction of CO2 into CO, electrochemical cells comprising said complexes, and a method for selectively reducing electrochemically CO2 into CO using said complexes.

Abstract: A photodetector for the detection of a light beam, comprising: a metal layer acting as a ground plane, a semiconductor layer covering the metal layer, wherein the semiconductor layer is made of at least two different materials forming an heterostructure, an array of metal pads covering the semiconductor layer, collecting the light beam and directing it towards the semiconductor layer, each of the metal pads, together with the semiconductor layer and the metal layer underneath it, the metal pads being interconnected by metal connection strips for conducting the detection current, wherein the semiconductor layer is completely etched in areas of the semiconductor layer that are neither covered by the metal pads nor by the connection strips, and wherein each metal pad forming an antenna for collecting incident photons of the light beam on an effective collection surface (??) of the light at least twice larger than a physical collection surface (A) of the semiconductor layer covered by said metal pad.

Abstract: The invention relates to a vector targeting thrombus, having t-PA binding property consisting of a thrombus targeting fucoidan moiety, which is covalently linked to one or more t-PA binding amino groups by the reducing end of the said fucoidan moiety.

Abstract: The present invention discloses compositions of novel DYRK1A protein inhibitors based on a 3,5-diarylazaindole motif and their preparation and use as medications in the treatment of cognitive disorders associated with dysfunction of DYRK1A protein, with Down's syndrome and with Alzheimer's disease.

Abstract: The present invention relates to catalysts for the production of CO gas through electrochemical CO2 reduction. In particular, the present invention relates to an electrochemical cell comprising an iron porphyrin as the catalyst for the CO2 reduction into CO, a method of performing electrochemical reduction of CO2 using said electrochemical cell thereby producing CO gas, and a method of performing electrochemical reduction of CO2 using said iron porphyrin catalyst thereby producing CO gas.

Abstract: The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.

Abstract: The present invention relates to a ligand molecule that specifically binds to KTR3DL2 at the surface of KTR3DL2 expressing malignant T-cells for the treatment of lymphomas. It also relates to the in vitro use of a level of expression of KIR3DL2 is a biomarker useful for diagnosing and/or monitoring a lymphoma.

Abstract: The present invention relates to a polymer obtained from the polymerization of: (i) at least one monomer of formula (I) (CH2?CR1)CO—K (I) wherein: K represents 0-Z or NH—Z, Z representing (CR2R3)m—CH3, (CH2—CH2—O)m—H, (CH2—CH2—O)m—CH3, (CH2)m—NR4R5 with m representing an integer from 1 to 30; R1, R2, R3, R4 and R5 independently represent H or a C1-C6 alkyl; and (ii) at least one bio-resorbable block copolymer cross-linker.